In conclusion, restoring the expression of RBM3, which results in suppression in the bone microenvironment, could be a possible beneficial therapeutic approach for inhibiting prostate cancer bone metastasis (Kaplan et al., 2021; Wang et al., 2021). This evidence concerns the gene RBM3 and prostate cancer.